Replies to post #122870 on Biotech Values

[DewDiligence]

Inasmuch as Roche has a majority stake in Chugai, they can’t be rid of this compound entirely :- )

[mcbio]

Roche Returns Development and Marketing Rights of SGLT2 Inhibitor CSG452 to Chugai

[Same class of drug as dapagliflozin. Roche has ended two diabetes drug development programs lately: GLP-1 taspoglutide and SGLT2 CSG452.]

LXRX's LX4211 is a dual SGLT2/SGLT1 inhibitor ( http://www.lexpharma.com/pipeline/lx4211.html ). I wonder if this news is bearish for their program as well, or maybe their drug is differentiated being a dual SGLT2/SGLT1 inhibitor.